论文部分内容阅读
目的评价丁苯酞治疗神经系统变性病及遗传性疾病的临床效果。方法选取2012年3月—2015年3月收治的神经系统变性病及遗传性疾病患者46例作为研究对象,随机分为对照组和观察组各23例。对照组患者采取常规药物进行对症治疗,观察组患者在对照组的基础上静脉滴注丁苯酞注射液进行治疗。分别采用自拟评分标准、多系统萎缩评分量表(unified multiple system atrophy rating scale,UMSARS)-I、世界神经病联合会国际合作共济失调量表(international cooperative ataxia rating scale,ICARS)对腓骨肌萎缩症、多系统萎缩、脊髓小脑共济失调患者的治疗效果进行评价。计量资料采用t检验,P<0.05为差异有统计学意义。结果治疗后,观察组腓骨肌萎缩症患者症状评分为(3.05±1.75)分,明显低于对照组的(6.06±2.21)分,差异有统计学意义(P<0.05)。治疗后,观察组多系统萎缩患者UMSARS-I语言、书写、使用餐具、穿衣、个人卫生、跌倒、直立症状、排尿功能评分分别为(1.31±0.12)、(1.84±0.06)、(2.01±0.10)、(2.15±0.05)、(1.95±0.12)、(2.26±0.07)、(2.20±0.11)、(2.01±0.10)分,均明显低于对照组的(1.50±0.12)、(2.10±0.15)、(2.18±0.12)、(2.29±0.12)、(2.18±0.10)、(2.54±0.08)、(2.51±0.12)、(2.20±0.14)分,差异均有统计学意义(均P<0.05)。治疗后,观察组脊髓小脑共济失调患者ICARS姿势和步态障碍、动态功能、语言障碍、眼球运动障碍评分分别为(7.32±6.25)、(7.62±3.01)、(1.00±0.38)、(0.80±0.38)分,均明显低于对照组的(12.65±4.24)、(10.87±3.20)、(1.40±0.34)、(1.11±0.25)分,差异均有统计学意义(均P<0.05)。结论神经系统变性病及遗传性疾病患者采用丁苯酞进行治疗,通过对线粒体功能的保护和改善,可获得显著的治疗效果,值得临床应用和推广。
Objective To evaluate the clinical efficacy of butylphthalide in the treatment of neurological degenerative and genetic diseases. Methods Forty-six patients with neurological degenerative and genetic diseases admitted to our hospital from March 2012 to March 2015 were selected as study subjects and randomly divided into control group and observation group of 23 cases each. Patients in the control group received symptomatic treatment with conventional drugs. The patients in the observation group were treated with butylphthalide by intravenous infusion on the basis of the control group. Respectively using the self-grading scale, the multiple system atrophy rating scale (UMSARS) -I, the International Federation of Ataxia rating scale (ICARS) Symptoms, multiple system atrophy, and treatment of patients with spinocerebellar ataxia. Measurement data using t test, P <0.05 for the difference was statistically significant. Results After treatment, the score of symptom in the Charcot-Marie-Tooth Syndrome patients was (3.05 ± 1.75) in the observation group, which was significantly lower than that in the control group (6.06 ± 2.21), the difference was statistically significant (P <0.05). After treatment, the scores of UMSARS-I language, writing, using tableware, dressing, personal hygiene, fall, erection symptom and voiding function in observation group with multiple system atrophy were 1.31 ± 0.12, 1.84 ± 0.06, 2.01 ± 0.10, 2.15 ± 0.05, 1.26 ± 0.07, 2.20 ± 0.11 and 2.01 ± 0.10, respectively, which were significantly lower than those in the control group (1.50 ± 0.12, 2.10 ± 0.15, 2.18 ± 0.12, 2.18 ± 0.10, 2.54 ± 0.08, 2.51 ± 0.12 and 2.20 ± 0.14, respectively (all P < 0.05). After treatment, the scores of ICARS and gait disorders, dynamic function, language impairment and eye movement disorder in the patients with Spinocerebellar ataxia in the observation group were (7.32 ± 6.25), (7.62 ± 3.01), (1.00 ± 0.38) and (0.80 ± 0.38), which were significantly lower than those of the control group (12.65 ± 4.24), (10.87 ± 3.20), (1.40 ± 0.34) and (1.11 ± 0.25) points, respectively (all P <0.05). Conclusions Patients with neurological degenerative diseases and genetic diseases are treated with butylphthalide. Significant therapeutic effects can be obtained through the protection and improvement of mitochondrial function, which is worthy of clinical application and promotion.